Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CMPI

Checkmate Pharmaceuticals (CMPI) Stock Price, News & Analysis

Checkmate Pharmaceuticals logo

About Checkmate Pharmaceuticals Stock (NASDAQ:CMPI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$10.50
$10.50
50-Day Range
$10.37
$10.50
52-Week Range
$2.00
$10.50
Volume
N/A
Average Volume
142,261 shs
Market Capitalization
$231.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Remove Ads
Receive CMPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CMPI Stock News Headlines

Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
See More Headlines

CMPI Stock Analysis - Frequently Asked Questions

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) posted its earnings results on Friday, November, 12th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.02.

Checkmate Pharmaceuticals (CMPI) raised $75 million in an initial public offering on Friday, August 7th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Checkmate Pharmaceuticals investors own include Athenex (ATNX), KLX Energy Services (KLXE), TherapeuticsMD (TXMD), BioNTech (BNTX), Bolt Biotherapeutics (BOLT), Nabors Industries (NBR) and NGL Energy Partners (NGL).

Company Calendar

Last Earnings
11/12/2021
Today
4/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPI
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.50 per share
Price / Book
4.20

Miscellaneous

Free Float
8,242,000
Market Cap
$231.40 million
Optionable
Not Optionable
Beta
-4.81
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CMPI) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners